nct_id: NCT03579836
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2018-07-09'
study_start_date: '2018-05-14'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Combination Product: Gemcitabine'
  - drug_name: 'Drug: BEY1107'
long_title: A Single Center, Open-label, Non-comparative, Phase I/II Clinical Trial
  to Assess the MTD, Safety and Efficacy of BEY1107 in Monotherapy and in Combination
  with Gemcitabine in Patient with Locally Advanced or Metastatic Pancreatic Cancer
last_updated: '2025-03-10'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: BeyondBio Inc.
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 75
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion criteria :'
- 1. Histologically or Cytologically confirmed with pancreatic ductal adenocarcinoma
  or undifferentiated carcinoma of the pancreas
- 2. At lease one measurable lesion according to RECIST v.1.1
- 3. Eastern Cooperative Oncology Group (ECOG) 0,1 or 2
- 4. Over 12 weeks of Life expectancy
- 5. Adequate Bone marrow, Renal and Liver function at screening
- 'Exclusion criteria :'
- 1. A patient who has treatment history with locally advanced and/or metastatic pancreatic
  cancer
- 2. Major surgery history at screening
- 3. Uncontrolled brain metastasis evidence
- 4. Active bacterial infection patients
- 5. Malignant tumor other than basal cell carcinoma, cervix carcinoma in situ and
  papillary thyroid cancer
- 6. expected Pregnant or breast-feeding patients
- 7. HIV, Active hepatitis B or C infection
- 8. A patient who has hypersensitivity with BEY1107 or Gemcitabine
short_title: Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine
  Combination in Patient with Pancreatic Cancer
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: BeyondBio Inc.
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: This study is a single center, open-label, non-comparative, phase I/II clinical
  trial to assess the maximum tolerated dose (MTD), safety and efficacy of BEY1107
  in monotherapy and in combination with gemcitabine in patient With locally advanced
  or metastatic pancreatic cancer.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Phase I-1 (#4 Cohort)
      arm_internal_id: 0
      arm_description: BEY1107 monotherapy, 4 Cohorts, 4 weeks (administered on a
        3-week-on and 1-week-off)
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: BEY1107'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Phase I-2 (#3 Cohort)
      arm_internal_id: 1
      arm_description: BEY1107 in combination with Gemcitabine, 3 Cohorts, 4 weeks
        (administered on a 3-week-on and 1-week-off)
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: BEY1107'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Combination Product: Gemcitabine'
        level_internal_id: 1
        level_suspended: N
    - arm_code: Phase II (#1 Cohort)
      arm_internal_id: 2
      arm_description: BEY1107 in combination with Gemcitabine, 6 Cycles / 24 weeks
        (administered on a 3-week-on and 1-week-off)
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: BEY1107'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Combination Product: Gemcitabine'
        level_internal_id: 1
        level_suspended: N
    match:
    - and:
      - or:
        - clinical:
            oncotree_primary_diagnosis: Pancreatic Adenocarcinoma
        - clinical:
            oncotree_primary_diagnosis: Undifferentiated Carcinoma of the Pancreas
      - clinical:
          age_numerical: '>=20'
          disease_status:
          - Locally Advanced
          - Metastatic
